GlobeNewswire: FibroGen, Inc. Contains the last 10 of 213 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T09:15:14ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/26/2852209/0/en/FibroGen-to-Present-at-23rd-Annual-Needham-Virtual-Healthcare-Conference.html?f=22&fvtc=4&fvtv=26127FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference2024-03-26T11:00:00Z<![CDATA[SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, from 3:00-3:40 PM Eastern Time. Company management will also participate in virtual one-on-one meetings with investors during the conference.]]>https://www.globenewswire.com/news-release/2024/03/11/2843607/0/en/FibroGen-Appoints-Deyaa-Adib-M-D-as-Chief-Medical-Officer.html?f=22&fvtc=4&fvtv=26127FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer2024-03-11T11:00:00Z<![CDATA[SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities. The appointment is effective March 11, 2024.]]>https://www.globenewswire.com/news-release/2024/02/26/2835501/0/en/FibroGen-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=26127FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results2024-02-26T21:06:00Z<![CDATA[• Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024]]>https://www.globenewswire.com/news-release/2024/02/26/2835490/0/en/FibroGen-Regains-All-Rights-to-Roxadustat-from-AstraZeneca-in-the-United-States-and-Other-AstraZeneca-Territories-Except-China-and-South-Korea.html?f=22&fvtc=4&fvtv=26127FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea2024-02-26T21:05:00Z<![CDATA[The FibroGen – AstraZeneca China Agreement for Roxadustat remains in place]]>https://www.globenewswire.com/news-release/2024/02/20/2831663/0/en/FibroGen-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=26127FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results2024-02-20T12:00:00Z<![CDATA[SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.]]>https://www.globenewswire.com/news-release/2024/02/05/2823393/0/en/FibroGen-To-Host-Part-I-of-Virtual-KOL-Investor-Event-Series-to-Review-Pamrevlumab-Clinical-Program-in-Pancreatic-Cancer-on-February-13-2024.html?f=22&fvtc=4&fvtv=26127FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 20242024-02-05T12:00:00Z<![CDATA[SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM ET. To register, click here.]]>https://www.globenewswire.com/news-release/2024/01/25/2816553/0/en/FibroGen-Announces-Completion-of-the-Pamrevlumab-Arm-in-Precision-Promise-Pancreatic-Cancer-Action-Network-s-Phase-2-3-Adaptive-Platform-Trial-for-Metastatic-Pancreatic-Cancer.html?f=22&fvtc=4&fvtv=26127FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer2024-01-25T12:00:00Z<![CDATA[SAN FRANCISCO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) announced graduation and completion of the pamrevlumab experimental arm in the Pancreatic Cancer Action Network's (PanCAN) Precision PromiseSM Phase 2/3 adaptive platform trial, which evaluates pamrevlumab in combination with the chemotherapy treatments gemcitabine and nab-paclitaxel for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Topline data from this registration study is anticipated in the second quarter of 2024.]]>https://www.globenewswire.com/news-release/2023/12/09/2793446/0/en/FibroGen-Presents-Data-from-Phase-3-MATTERHORN-Trial-of-Roxadustat-in-Patients-with-Anemia-of-Lower-Risk-Transfusion-Dependent-Myelodysplastic-Syndromes-at-American-Society-of-Hema.html?f=22&fvtc=4&fvtv=26127FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting2023-12-09T22:02:00Z<![CDATA[A post hoc analysis of patients with higher transfusion burden at baseline showed a larger percentage of patients achieved transfusion independence ≥ 56 days with roxadustat vs. placebo (36.1% vs 11.5%; p=0.047ǂ).]]>https://www.globenewswire.com/news-release/2023/11/06/2774471/0/en/FibroGen-Reports-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=26127FibroGen Reports Third Quarter 2023 Financial Results2023-11-06T21:01:00Z<![CDATA[SAN FRANCISCO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2023 and provided an update on the Company’s recent developments.]]>https://www.globenewswire.com/news-release/2023/10/23/2764572/0/en/FibroGen-to-Report-Third-Quarter-2023-Financial-Results.html?f=22&fvtc=4&fvtv=26127FibroGen to Report Third Quarter 2023 Financial Results2023-10-23T11:00:00Z<![CDATA[SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.]]>